Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon for Chronic Insomnia
NCT00672724Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Ramelteon 8 mg QD with Placebo (2 arms). Primary endpoint: Mean Subjective Sleep Latency at Day 8. Started Feb 2005; status: terminated.
02
Drugs
ramelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00672724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672724.